Left Ventricular Hypertrabeculation and Prognosis in Dilated Cardiomyopathy
Authors:
- Nerea Mora-AyestaránNMNerea Mora-Ayestarán
- Noemi Ramos-LopezNRNoemi Ramos-Lopez
- Juan Pablo OchoaJOJuan Pablo Ochoa
- Amaia Yuan IbargoyenAIAmaia Yuan Ibargoyen
- Ahmad S. AminAAAhmad S. Amin
- María Gallego-DelgadoMGMaría Gallego-Delgado
- Guillem Casas-MasnouGCGuillem Casas-Masnou
- Marina Navarro-PeñalverMNMarina Navarro-Peñalver
- Jose María Larrañaga-MoreiraJLJose María Larrañaga-Moreira
Open Access
- 4 August 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (5) , 440-453
Abstract
BACKGROUND: Left ventricular (LV) hypertrabeculation, formerly termed LV noncompaction, is a heterogeneous myocardial entity linked to adverse cardiovascular outcomes. This study evaluated embolic risk in patients with dilated cardiomyopathy (DCM) according to the presence of hypertrabeculation and examined its prevalence and prognostic relevance across DCM genotypes. METHODS: Clinical data from 1160 patients with DCM evaluated by cardiac magnetic resonance imaging and genetic testing (n=997 [86%]) were collected from 22 international centers. End points included embolic events, advanced heart failure events, and major ventricular arrhythmias. RESULTS: LV hypertrabeculation was identified in 354 patients (30.5%) by fractal analysis and in 343 (29.7%) according to Petersen criteria, with good concordance. After a median follow-up of 5.1 years (interquartile range, 2.8–7.4), embolic events occurred in 37 patients (3.2%), advanced heart failure in 62 (5.3%), and major ventricular arrhythmias in 136 (11.7%). Hypertrabeculation was not associated with increased embolic risk (hazard ratio, 1.5 [95% CI, 0.75–3.00]), even among patients in sinus rhythm with LV ejection fraction ≤40% (hazard ratio, 1.89 [95% CI, 0.7–5.5]). In contrast, atrial fibrillation and reduced LV ejection fraction were associated with embolic events (both P TTN (38%), and genotype-negative status (33%), and the lowest prevalence observed among those with variants in cytoskeletal/Z-disk (7%) and nuclear envelope (5%) genes. Hypertrabeculation was not associated with adverse outcomes within any genotype. CONCLUSIONS: Although LV hypertrabeculation is common in DCM, it is not associated with worse outcomes and should not prompt differential clinical management. The embolic risk in patients with DCM and hypertrabeculation is low, including in those with reduced LV ejection fraction without atrial fibrillation, and does not support prophylactic anticoagulation in these patients.Keywords
This publication has 49 references indexed in Scilit:
- Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non‐ischaemic dilated cardiomyopathyEuropean Journal of Heart Failure, 2022
- A Proposed Strategy for Anticoagulation Therapy in Noncompaction CardiomyopathyESC Heart Failure, 2021
- 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathyHeart Rhythm, 2019
- Left ventricular non‐compaction: Prevalence in congenital heart diseaseInternational Journal of Cardiology, 2013
- Diagnosis, severity grading and prognosis of left ventricular non-compaction using cardiovascular magnetic resonanceInternational Journal of Cardiology, 2013
- Predictors of Adverse Outcome in Adolescents and Adults With Isolated Left Ventricular NoncompactionThe American Journal of Cardiology, 2012
- Frequency of Stroke and Embolism in Left Ventricular Hypertrabeculation/NoncompactionThe American Journal of Cardiology, 2011
- Isolated Left Ventricular Noncompaction SyndromeThe American Journal of Cardiology, 2009
- Clinical Features of Isolated Ventricular Noncompaction in Adults Long-Term Clinical Course, Echocardiographic Properties, and Predictors of Left Ventricular FailureJournal of Cardiac Failure, 2006
- Different Types of Cardiomyopathy Associated With Isolated Ventricular NoncompactionThe American Journal of Cardiology, 2006